Table 1.
Demographical and clinicopathological features of 21 AML patients receiving clofarabine and high-dose cytosine arabinoside
| Number | Gender | Age | Remission duration | Prior treatment (number) | Cytogenetics | FLT3 ITD |
|---|---|---|---|---|---|---|
| Primary refractory | ||||||
| 4 | M = 2 | 49 (34–61) years | N.A. | 3 + 7 (N = 4) | Favourable (N = 0) | Positive (N = 0) |
| F = 2 | ICE (N = 3) | Intermediate (N = 2) | Negative (N = 4) | |||
| MTZ + MAra-C (N = 3) | Adverse (N = 2) | |||||
| FLAG (N = 1) | ||||||
| First relapse | ||||||
| 11 | M = 4 | 45 (22–62) years | 5 (2–12) months | 3:7 (N = 11) | Favourable (N = 1) | Positive (N = 1) |
| F = 7 | HDAra-C (N = 5) | Intermediate (N = 7) | Negative (N = 7) | |||
| ICE (N = 8) | Adverse (N = 3) | Not available (N = 3) | ||||
| MTZ + MAra-C (N = 3) | ||||||
| FLAG (N = 2) | ||||||
| Allogeneic HSCT (N = 2) | ||||||
| Second relapse | ||||||
| 6 | M = 4 | 44 (22–59) years | 4.5 (2–12) months | 3:7 (N = 6) | Favourable (N = 0) | Positive (N = 1) |
| F = 2 | HDAra-C (N = 3) | Intermediate (N = 4) | Negative (N = 4) | |||
| ICE (N = 6) | Adverse (N = 1) | Not available (N = 1) | ||||
| MTZ + MAra-C (N = 3) | Not available (N = 1) | |||||
| FLAG (N = 1) | ||||||
| Allogeneic HSCT (N = 1) | ||||||
AML acute myeloid leukaemia; age median and range in parenthesis; remission duration time from last remission in relapsed patients, median and range in parenthesis; FLT3 ITD FLT3 gene internal tandem duplication; M male; F female; N number of patients; 3 + 7 3 days of daunorubicin (50 mg/m2) + 7 days of Ara-C (100 mg/m2); HDAra-C 3 g/m2 every 12 h for four doses; ICE 5 days of idarubicin (6 mg/m2), 5 days of Ara-C (600 mg/m2), 3 days of etoposide (150 mg/m2); MTZ + MAra-C 3 days of mitoxantrone (12 mg/m2) + 4 days of Ara-C (1,000 mg/m2); FLAG 5 days of fludarabine (30 mg/m2) + 5 days of Ara-C (2,000 mg/m2); HSCT haematopoietic stem cell transplantation with myeloablative conditioning regimens